@article{3108439,
    title = "Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer",
    author = "Pezaro, C.J. and Omlin, A. and Mastris, K. and Attard, G. and Beer, T.M. and Chi, K.N. and Chowdhury, S. and Davis, I.D. and Drake, C.G. and de Bono, J.S. and Efstathiou, E. and Gravis, G. and Higano, C.S. and Hussain, M. and James, N. and Logothetis, C.J. and Morgans, A. and Parker, C. and Ryan, C.J. and Saad, F. and Sartor, O. and Small, E.J. and Sternberg, C.N. and Sweeney, C.J. and Tannock, I. and Tombal, B. and Gillessen, S. and ANZUP Consumer Advisory Panel",
    journal = "Annals of Oncology",
    year = "2017",
    volume = "28",
    number = "8",
    pages = "1692-1694",
    publisher = "Oxford University Press",
    issn = "0923-7534, 1569-8041",
    doi = "10.1093/annonc/mdx312",
    keywords = "abiraterone;  abiraterone acetate;  docetaxel;  enzalutamide;  testosterone, advanced cancer;  androgen deprivation therapy;  cancer survival;  castration resistant prostate cancer;  Editorial;  human;  measurement precision;  medical terminology;  metastatic prostate cancer;  overall survival;  practice guideline;  priority journal;  prostate cancer;  stigma;  castration resistant prostate cancer;  classification;  male;  nomenclature, Humans;  Male;  Prostatic Neoplasms, Castration-Resistant;  Terminology as Topic"
}